Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04119388
Other study ID # 69HCL18_0747
Secondary ID ID-RCB
Status Completed
Phase N/A
First received
Last updated
Start date November 4, 2019
Est. completion date October 14, 2022

Study information

Verified date January 2023
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functionals limitations and no adapted physicals activity(APA). The hypothesis is that an Adapted physique activity could improve access of activity for patients with Osteogenesis Imperfecta (OI). The aim of the study is to evaluate benefice of APA,improve aerobic capacity, cardiovascular and bone benefits, and gain of quality of life. Children with OI between 6 and 18 years old will have a program of supervised "adapted training program" during one year. The program is adapted at each individual and without risk for the patient.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date October 14, 2022
Est. primary completion date October 14, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria: - Child with osteogenesis imperfecta - Child followed in the Reference centre for constitutional bone diseases in the Hôpital Femme Mère Enfant - Parent (s) / legal guardian who has been informed of the study and has accepted participation in the study by signing the consent. - Patient benefiting from a social security scheme Exclusion Criteria: - Medical and surgical contraindications to adapted physical activity.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Adapted sports practices
Adapted sports practices for 30 minutes twice a week

Locations

Country Name City State
France Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6 minutes walk test Distance traveled (in meters) in 6 minutes Month 0
Primary 6 minutes walk test Distance traveled (in meters) in 6 minutes Month 6
Primary 6 minutes walk test Distance traveled (in meters) in 6 minutes Month 12
Secondary Weight weight in kilograms will be measured with a scale Month 0
Secondary Weight weight in kilograms will be measured with a scale Month 6
Secondary Weight weight in kilograms will be measured with a scale Month 12
Secondary Height Size in meter measured with a meter Month 0
Secondary Height Size in meter measured with a meter Month 6
Secondary Height Size in meter measured with a meter Month 12
Secondary body mass index calculated with weight and height Month 0
Secondary body mass index calculated with weight and height Month 6
Secondary body mass index calculated with weight and height Month 12
Secondary blood pressure measurement of blood pressure (cm Hg) Month 0
Secondary blood pressure measurement of blood pressure (cm Hg) Month 6
Secondary blood pressure measurement of blood pressure (cm Hg) Month 12
Secondary phosphocalcic biologic parameters Ionosodium (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters potassium (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters calcium (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters chlore (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters bicarbonates (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters glucose (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters urea (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters creatinemia (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters phosphorus (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters proteinemia (g/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters Vitamin D (nmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters 1-25 OH vitamin D (pmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters PTH (ng/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters alkaline bone phosphatases (U/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters CTX (pg/ml)crosslaps Month 0 and Month 12
Secondary phosphocalcic biologic parameters osteocalcin (µg/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters ferritin (µg/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters calciuria (mmol/L) Month 0 and Month 12
Secondary phosphocalcic biologic parameters Ionosodium (mmol/L) potassium (mmol/L), calcium (mmol/L), chlore (mmol/L), bicarbonates (mmol/L), glucose (mmol/L), urea (mmol/L), creatinemia (mmol/L), phosphorus (mmol/L), proteinemia (g/L), Vitamin D (nmol/L), 1-25 OH vitamin D (pmol/L), PTH (ng/L), alkaline bone phosphatases (U/L), CTX (pg/ml)crosslaps, osteocalcin (µg/L), NFS, ferritin (µg/L), blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L), calciuria (mmol/L), urinary creatinin (mmol/L). Month 0 and Month 12
Secondary ration lean mass / fat mass Dual-energy X-ray absorptiometry (DXA) Month 0
Secondary ration lean mass / fat mass Dual-energy X-ray absorptiometry (DXA) Month 12
Secondary Respiratory Functional Exploration Month 0
Secondary Respiratory Functional Exploration Month 12
Secondary Thickness intima / media echography Month 0
Secondary Parameters of the connected watch : number of steps data recovery of the connected watch Month 0 and Month 6 and Month 12
Secondary Parameters of the connected watch : distance traveled data recovery of the connected watch Month 0 and Month 6 and Month 12
Secondary Parameters of the connected watch : calories consumption data recovery of the connected watch Month 0 and Month 6 and Month 12
Secondary Ratio thickness intima / media echography Month 12
Secondary Bone mineral density Dual-energy X-ray absorptiometry (DXA) Month 0
Secondary Bone mineral density Dual-energy X-ray absorptiometry (DXA) Month 12
Secondary Number of new fractures Month 1
Secondary Number of new fractures Month 3
Secondary Number of new fractures Month 6
Secondary Number of new fractures Month 9
Secondary Number of new fractures Month 12
Secondary Quality of life questionnaire : PedsQL Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are
Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)
Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)
Month 0
Secondary Quality of life questionnaire : PedsQL Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are
Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)
Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)
Month 6
Secondary Quality of life questionnaire : PedsQL Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are
Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)
Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)
Month 12
See also
  Status Clinical Trial Phase
Completed NCT03557567 - NGS Strategy Effectiveness in Molecular Diagnosis
Not yet recruiting NCT05559801 - Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Phase 1/Phase 2
Active, not recruiting NCT02531087 - Urinary Biomarkers of OI Pathobiology
Completed NCT01713231 - Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta Phase 4
Completed NCT00655681 - Prevention of Post Operative Bone Loss in Children N/A
Recruiting NCT06065111 - Study of Osteogenesis Imperfecta Tendon
Withdrawn NCT03216486 - An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Phase 2
Recruiting NCT06086613 - A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers Phase 1
Completed NCT04009733 - Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study N/A
Completed NCT04231916 - High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta N/A
Active, not recruiting NCT02814591 - Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
Completed NCT00982124 - An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta Phase 3
Completed NCT00001305 - Growth Hormone Therapy in Osteogenesis Imperfecta Phase 3
Terminated NCT01679080 - The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta Phase 2
Completed NCT00106028 - Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children Phase 3
Recruiting NCT04152551 - Effects of Bisphosphonates on OI-Related Hearing Loss Phase 4
Completed NCT00705120 - Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation Phase 1
Recruiting NCT04169568 - Osteogenesis Imperfecta Blood Pressure Study
Completed NCT03064074 - Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta Phase 1
Not yet recruiting NCT05258019 - Site Preservation After Tooth Extraction